Invion Stock

Invion LT Debt/Equity

Long-Term Debt to Equity Ratio of Invion (IVX.AX) as of Sep 12, 2026.

LT Debt/Equity

0.00

Last updated:

Long-Term Debt to Equity Ratio of Invion is 2026 0.00 . Long-Term Debt to Equity Ratio of Invion was 2025 0.00 . It decreases by % lower compared to the previous year.

The Invion LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2016
0.20 AUD
Jan 1, 2017
0.00 AUD
Jan 1, 2018
0.00 AUD
Jan 1, 2019
0.00 AUD
Jan 1, 2020
0.00 AUD
Jan 1, 2021
0.00 AUD
Jan 1, 2022
0.00 AUD
The Invion LT Debt/Equity history
YEARLT Debt/EquityYoY
0.00
0.00
0.00
0.00
0.00
0.00-100.00%
0.20
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Invion since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Invion with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Invion

All Key Metrics — Invion